Scemblix® continued to show superior efficacy and favorable safety and tolerability profile at week 144 in newly diagnosed CML
Growing improvement in major molecular response (MMR) rates demonstrated with Scemblix vs. all standard-of-care TKIs including imatinib and second generation (2G) TKIs1 Clinically relevant 15.2% higher MMR rate achieved with...
Why this byte is shareable
Signal quality
observed
Confidence badge and source context included.
Entity anchor
AI News
Clear company or model context for distribution.
Export ready
1200 x 630 card
Optimized for X, LinkedIn, and chat previews.
Why it matters
AI News is pushing on evals and safety guardrails, which matters for builders hardening agents against prompt injection, reasoning leaks, and other failure modes.
Suggested launch post
Use this in X threads, community posts, internal team chats, or launch recaps.
Scemblix® continued to show superior efficacy and favorable safety and tolerability profile at week 144 in newly diagnosed CML Why it matters: AI News is pushing on evals and safety guardrails, which matters for builders hardening agents against prompt injection, reasoning le...
Permalink: https://a2zai.ai/bytes/scemblix-continued-to-show-superior-efficacy-and-favorable-safety-and-tolerabili-ee257885
Social card: https://a2zai.ai/bytes/scemblix-continued-to-show-superior-efficacy-and-favorable-safety-and-tolerabili-ee257885/opengraph-image